Major trial to determine best drug for rare autoimmune disease
NCT ID NCT07010302
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares five FDA-approved drugs—rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab—to see which best prevents relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that can cause vision loss and paralysis. About 160 adults who test positive for a specific antibody will be randomly assigned to one of the drugs and followed for up to four years. The goal is to find the most effective and safest treatment to help patients and doctors make informed choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab, ravulizumab, inebilizumab, satralizumab, eculizumab
What this could lead to
If this trial succeeds, it could identify which of these five drugs best prevents relapses and has fewer side effects, helping patients and doctors choose the most effective treatment for NMOSD.
What could go wrong
This is a comparative effectiveness trial, not a test of new drugs. All medications are already approved, so the main uncertainty is which works best in real-world use. Results may not apply to all patients, and side effects are possible with each drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMOSD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••